Company Sarepta Therapeutics, Inc. Sao Paulo
Equities
S1RP34
BRS1RPBDR005
Biotechnology & Medical Research
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
32.56 BRL | -2.08% | -1.96% | +41.81% |
Business Summary
Number of employees: 1,314
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
RNA-targeted Therapeutics, Gene Therapy and Other Genetic Therapeutic Modalities
100.0
%
| 933 | 100.0 % | 1,243 | 100.0 % | +33.26% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 933 | 100.0 % | 1,243 | 100.0 % | +33.26% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Douglas Ingram
CEO | Chief Executive Officer | 61 | 25/06/17 |
Ian Estepan
DFI | Director of Finance/CFO | 48 | 31/12/14 |
Bilal Arif
CTO | Chief Tech/Sci/R&D Officer | - | - |
Chief Tech/Sci/R&D Officer | 48 | 31/05/18 | |
Will Tilton
HRO | Human Resources Officer | - | - |
Alison Nasisi
HRO | Human Resources Officer | - | - |
Dallan Murray
PRN | Corporate Officer/Principal | - | 31/12/12 |
Diane Berry
PRN | Corporate Officer/Principal | - | 30/11/11 |
Ryan Brown
LAW | General Counsel | 46 | 31/12/17 |
Joseph Bratica
AUD | Comptroller/Controller/Auditor | 60 | 28/02/17 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Douglas Ingram
CEO | Chief Executive Officer | 61 | 25/06/17 |
M. Wilsey
CHM | Chairman | 71 | 30/03/09 |
Richard Barry
BRD | Director/Board Member | 65 | 01/06/15 |
Director/Board Member | 86 | 31/05/10 | |
Stephen Mayo
BRD | Director/Board Member | 62 | 15/11/21 |
Claude Nicaise
BRD | Director/Board Member | 71 | 01/06/15 |
Michael Chambers
BRD | Director/Board Member | - | 01/06/22 |
Kathryn Boor
BRD | Director/Board Member | 65 | 01/06/22 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 94,523,766 | 89,825,408 ( 95.03 %) | 0 | 95.03 % |
Company contact information
Sarepta Therapeutics, Inc.
215 First Street Suite 415
02142, Cambridge
+617 274 4000
http://www.sareptatherapeutics.comSector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+10.79% | 115B | |
+11.65% | 106B | |
-6.20% | 24.69B | |
-2.33% | 21.97B | |
-6.03% | 19.27B | |
-13.41% | 17.56B | |
-40.50% | 17.32B | |
+6.64% | 14.03B | |
-34.35% | 7.77B |
- Stock Market
- Equities
- SRPT Stock
- S1RP34 Stock
- Company Sarepta Therapeutics, Inc.